Clinical Trials Logo

Clinical Trial Summary

This study is a single arm, pilot study of Sunitinib in patient with RET fusion positive, FGFR2 fusion/FGFR mutation Refractory solid tumor and/or specific sensitivity to Sunitinib by Avatar scan that has progressed following standard therapy or that has not responded to standard therapy or for which there is no standard therapy. To investigate the efficacy and safety of Sunitinib in patient with Refractory solid tumor.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02691793
Study type Interventional
Source Samsung Medical Center
Contact
Status Completed
Phase Phase 4
Start date November 20, 2017
Completion date November 19, 2019

See also
  Status Clinical Trial Phase
Completed NCT00404508 - A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors Phase 2
Completed NCT02450136 - Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors N/A
Completed NCT02596503 - A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors Phase 1
Completed NCT00759928 - PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors Phase 1
Recruiting NCT06150365 - Single Arm Clinical Study on the Safety and Efficacy of Personalized KSX01-TCRT in Patients With Advanced Solid Tumors Early Phase 1
Completed NCT01247168 - An Open-Label, Dose-Escalation Study of AZD2461 Phase 1
Completed NCT00665990 - Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia Phase 1
Completed NCT02450149 - Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors N/A
Completed NCT02691767 - Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors N/A
Terminated NCT00664586 - A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors Phase 1
Recruiting NCT05811975 - KSX01-TCRT Injection Project in Solid Tumors Early Phase 1
Completed NCT03810742 - Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors Phase 1
Terminated NCT03096340 - Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer Phase 1
Completed NCT02450123 - Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors N/A
Completed NCT02383368 - A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma Phase 1
Completed NCT00394446 - Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors Phase 1
Completed NCT03052205 - A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors Phase 1
Completed NCT02482441 - A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 Phase 1
Recruiting NCT03739827 - Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
Recruiting NCT05150457 - Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors Phase 1